Even if several studies have shown an increase in adverse outcomes, the study by Gurlek et al found no relation between aCL antibodies and recurrent cardiovascular events in ACS patients suffering from APS/SLE.8 Another study by Sletnes et al29 failed to prove that aCL is an independent risk for mortality or recurrent MI. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.